$DAWN
Day One Biopharmaceuticals, Inc.

2022 Q1 Form 10-Q Financial Statement

#000095017022009734 Filed on May 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.75M $3.454M $4.680M
YoY Change 268.99% 327.48% 363.37%
% of Gross Profit
Research & Development $15.00M $12.63M $9.100M
YoY Change 18.77% 1214.46% -34.53%
% of Gross Profit
Depreciation & Amortization $6.000K $5.000K $10.00K
YoY Change 20.0%
% of Gross Profit
Operating Expenses $27.75M $16.09M $13.78M
YoY Change 72.5% 809.33% -7.58%
Operating Profit -$27.75M -$16.09M
YoY Change 72.5%
Interest Expense $2.000K -$7.000K -$30.03M
YoY Change -128.57% -96.83% 1343.75%
% of Operating Profit
Other Income/Expense, Net -$1.000K -$8.000K -$30.00K
YoY Change -87.5% 300.0%
Pretax Income -$27.75M -$16.10M -$43.84M
YoY Change 72.33% 708.28% 158.19%
Income Tax
% Of Pretax Income
Net Earnings -$27.75M -$15.18M -$40.51M
YoY Change 82.76% 889.06% 220.74%
Net Earnings / Revenue
Basic Earnings Per Share -$0.48
Diluted Earnings Per Share -$475.3K -$251.6K -$671.4K
COMMON SHARES
Basic Shares Outstanding 61.95M
Diluted Shares Outstanding 58.38M

Balance Sheet

Concept 2022 Q1 2021 Q1 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $262.7M $154.9M $43.73M
YoY Change 69.65% 60.01%
Cash & Equivalents $262.7M $154.9M $43.73M
Short-Term Investments
Other Short-Term Assets $267.4M $3.885M $45.07M
YoY Change 6782.06% 450610.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $267.4M $158.8M $45.07M
YoY Change 68.42% 64.85%
LONG-TERM ASSETS
Property, Plant & Equipment $66.00K $435.0K $77.00K
YoY Change -84.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $165.0K $1.690M $110.0K
YoY Change -90.24%
Other Assets
YoY Change
Total Long-Term Assets $411.0K $2.125M $590.0K
YoY Change -80.66%
TOTAL ASSETS
Total Short-Term Assets $267.4M $158.8M $45.07M
Total Long-Term Assets $411.0K $2.125M $590.0K
Total Assets $267.8M $160.9M $45.66M
YoY Change 66.45% 67.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $701.0K $686.0K $202.0K
YoY Change 2.19% 188.57%
Accrued Expenses $7.088M $2.373M $1.596M
YoY Change 198.69% 239.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.176M $3.066M $1.996M
YoY Change 166.67% -1.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $159.0K $200.0K
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $159.0K $200.0K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.176M $3.066M $1.996M
Total Long-Term Liabilities $0.00 $159.0K $200.0K
Total Liabilities $8.176M $8.008M $2.200M
YoY Change 2.1% -70.71%
SHAREHOLDERS EQUITY
Retained Earnings -$155.2M -$56.84M
YoY Change
Common Stock $6.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $259.6M -$68.85M -$54.21M
YoY Change
Total Liabilities & Shareholders Equity $267.8M $160.9M $45.66M
YoY Change 66.45% 67.01%

Cashflow Statement

Concept 2022 Q1 2021 Q1 2020 Q4
OPERATING ACTIVITIES
Net Income -$27.75M -$15.18M -$40.51M
YoY Change 82.76% 889.06% 220.74%
Depreciation, Depletion And Amortization $6.000K $5.000K $10.00K
YoY Change 20.0%
Cash From Operating Activities -$21.56M -$9.743M -$5.939M
YoY Change 121.32% 367.29% 31.39%
INVESTING ACTIVITIES
Capital Expenditures $15.00K $3.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$8.000M
YoY Change -100.0%
Cash From Investing Activities -$15.00K -$8.000M $3.000K
YoY Change -99.81% 8990.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 128.9M 29.98M
YoY Change -3.01%
NET CHANGE
Cash From Operating Activities -21.56M -9.743M -5.939M
Cash From Investing Activities -15.00K -8.000M 3.000K
Cash From Financing Activities 128.9M 29.98M
Net Change In Cash -21.58M 111.1M 24.04M
YoY Change -119.41% -5214.68% -8.89%
FREE CASH FLOW
Cash From Operating Activities -$21.56M -$9.743M -$5.939M
Capital Expenditures $15.00K $3.000K
Free Cash Flow -$21.58M -$9.743M -$5.942M
YoY Change 121.47% 387.88% 31.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2022Q1 dei City Area Code
CityAreaCode
650
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
484-0899
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
DAWN
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
CY2022Q1 dawn Payments To Acquire Process Research And Development Assets
PaymentsToAcquireProcessResearchAndDevelopmentAssets
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001845337
CY2022Q1 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
CY2022Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
CY2022Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dawn Deferred Offering Costs Not Yet Paid
DeferredOfferingCostsNotYetPaid
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-40431
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
DAY ONE BIOPHARMACEUTICALS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2415215
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
395 Oyster Point Blvd.
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 217
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61911929
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
262731000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
284309000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4637000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21563000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9743000
CY2021Q1 dawn Payments To Acquire Process Research And Development Assets
PaymentsToAcquireProcessResearchAndDevelopmentAssets
8000000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5059000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
267368000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
289368000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
66000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
180000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
227000
CY2022Q1 dawn Deposits And Other Longterm Assets Non Current
DepositsAndOtherLongtermAssetsNonCurrent
165000
CY2021Q4 dawn Deposits And Other Longterm Assets Non Current
DepositsAndOtherLongtermAssetsNonCurrent
169000
CY2022Q1 us-gaap Assets
Assets
267779000
CY2021Q4 us-gaap Assets
Assets
289821000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
701000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1744000
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7304000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6709000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
171000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
204000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8176000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8657000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16000
CY2022Q1 us-gaap Liabilities
Liabilities
8176000
CY2021Q4 us-gaap Liabilities
Liabilities
8673000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61911929
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61911929
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61952292
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61952292
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
6000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
414831000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
408629000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-155234000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-127487000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
259603000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
281148000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
267779000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
289821000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15003000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12632000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12745000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3454000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
27748000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
484000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
16086000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-27748000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16086000
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2000
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-7000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-27747000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-16101000
CY2022Q1 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
0
CY2021Q1 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
-919000
CY2022Q1 dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-27747000
CY2021Q1 dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-15182000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.58
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58382444
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5892145
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
281148000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6202000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27747000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
259603000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-54205000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
538000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-15182000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-68849000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-27747000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-16101000
CY2021Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
8000000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6202000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
538000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
47000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
44000
CY2021Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
7000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-422000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2542000
CY2022Q1 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-4000
CY2021Q1 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
26000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1043000
CY2022Q1 dawn Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
595000
CY2021Q1 dawn Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-101000
CY2022Q1 dawn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-49000
CY2021Q1 dawn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-51000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1015000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8000000
CY2021Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
129757000
CY2021Q1 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
872000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
128885000
CY2022Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-21578000
CY2021Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
111142000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
284309000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43728000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
262731000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154870000
CY2021Q1 dawn Deferred Offering Costs Not Yet Paid
DeferredOfferingCostsNotYetPaid
686000
CY2021Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
167000000.0
CY2021Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
17000000.0
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
4719605
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
2.325-for-1
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to, the valuation of share-based awards, the valuation of deferred tax assets and income tax uncertainties, and accruals for research and development activities. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p>
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
874000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2099000
CY2022Q1 dawn Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
3365000
CY2021Q4 dawn Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
1945000
CY2022Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
398000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1098000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
732000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
387000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
104000
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7304000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6709000
CY2022Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P0Y9M18D
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4637000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5059000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
107000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
93000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
41000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
36000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
66000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57000
CY2022Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1648000
CY2021Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
3308000
CY2022Q1 dawn Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
4171000
CY2021Q4 dawn Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2565000
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
158000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
18000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
176000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
171000
CY2018Q4 dawn Number Of Directors Entitled To Be Elected By The Holders Of Common Stock
NumberOfDirectorsEntitledToBeElectedByTheHoldersOfCommonStock
2
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10692078
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
0
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6202000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
538000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-27747000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-16101000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
919000
CY2022Q1 dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-27747000
CY2021Q1 dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-15182000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.58
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58382444
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5892145
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10788025
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37524206
CY2021Q2 dawn Adjustment To Additional Paid In Capital Loss On Conversion Of Temporary Equity Into Permanent Equity
AdjustmentToAdditionalPaidInCapitalLossOnConversionOfTemporaryEquityIntoPermanentEquity
100000000.0
CY2022Q1 dawn Defined Contribution Plan Employer Matching Contribution
DefinedContributionPlanEmployerMatchingContribution
200000
CY2021Q1 dawn Defined Contribution Plan Employer Matching Contribution
DefinedContributionPlanEmployerMatchingContribution
0
CY2022Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1100000

Files In Submission

Name View Source Status
0000950170-22-009734-index-headers.html Edgar Link pending
0000950170-22-009734-index.html Edgar Link pending
0000950170-22-009734.txt Edgar Link pending
0000950170-22-009734-xbrl.zip Edgar Link pending
dawn-20220331.htm Edgar Link pending
dawn-20220331.xsd Edgar Link pending
dawn-20220331_cal.xml Edgar Link unprocessable
dawn-20220331_def.xml Edgar Link unprocessable
dawn-20220331_htm.xml Edgar Link completed
dawn-20220331_lab.xml Edgar Link unprocessable
dawn-20220331_pre.xml Edgar Link unprocessable
dawn-ex31_1.htm Edgar Link pending
dawn-ex31_2.htm Edgar Link pending
dawn-ex32_1.htm Edgar Link pending
dawn-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img11716408_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending